Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa
hegazy, E., Zahra, S., Shoeib, S., Taha, M. (2022). Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa. EKB Journal Management System, 31(4), 123-129. doi: 10.21608/ejmm.2022.262698
Eman elsayed hegazy; Shaimaa Waheed Zahra; Sarah M. Shoeib; Marwa S. Taha. "Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa". EKB Journal Management System, 31, 4, 2022, 123-129. doi: 10.21608/ejmm.2022.262698
hegazy, E., Zahra, S., Shoeib, S., Taha, M. (2022). 'Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa', EKB Journal Management System, 31(4), pp. 123-129. doi: 10.21608/ejmm.2022.262698
hegazy, E., Zahra, S., Shoeib, S., Taha, M. Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa. EKB Journal Management System, 2022; 31(4): 123-129. doi: 10.21608/ejmm.2022.262698

Evaluation of In vitro Activity of Cefiderocol and Ceftolozane-Tazobactam against Extended-Spectrum β-Lactamase–Producing Coliform and Multidrug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa

Egyptian Journal of Medical Microbiology
Volume 31, Issue 4, October 2022, Page 123-129  XML PDF (376.91 K)
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2022.262698
View on SCiNiTO View on SCiNiTO
Authors
Eman elsayed hegazy email orcid 1; Shaimaa Waheed Zahra2; Sarah M. Shoeib3; Marwa S. Taha4
1medical microbiology and immunology department ,faculty of medicine, Tanta university
21. Department of Medical Microbiology and Immunology, Faculty of Medicine, Tanta University
32. Department of Clinical Pathology, Faculty of Medicine, Tanta University
4Department of Medical Microbiology and Immunology, Faculty of Medicine, Tanta University
Abstract
Background: A worrisome escalation in multidrug-resistant (MDR) Gram-negative bacterial infections which are accompanied with worse outcomes due to inadequate treatment options. There is an imperative requirement to explore new antimicrobials to oppose these resistant strains. Objectives: Assessment of antibacterial activity of Cefiderocol and Ceftolozane-Tazobactam against ESBL–Producing coliform and MDR A. baumannii and P. aeruginosa. Methodology: A total of 332 clinical samples were obtained from surgical ICU cases. Pathogenic microorganisms were identified. Antibiotic susceptibility was done for gram negative isolates. Third-generation cephalosporins resistant coliforms were screened for ESBL detection. Ceftolozane-Tazobactam and Cefiderocol activity on ESBL coliform and MDR P. aeruginosa and A. baumannii isolates was investigated. Results: The susceptibility of both ESBL E. coli, K. pneumoniae, MDR P. aeruginosa, and A. baumannii to ceftolozane/tazobactam was 77%, 70% ,63% and 58% respectively. ESBL E. coli and K. pneumonaie    exhibited MIC 50/90 value of (0.19/0.25μg/mL) and (0.25/0.5μg/mL) for ceftolozane/tazobactam respectively.  MDR P. aeruginosa   showed MIC 50/90 value (2/4μg/mL). MDR A. baumannii exhibited high MIC 50/90   value (16/24μg/mL).  Cefiderocol was 100% effective against most isolates with different MIC 50/90 values. For ESBL-E. coli and K. pneumoniae, the MIC 50/90 value was (0.5/1.5μg/mL). For MDR P. aeruginosa and A. baumannii, the MIC 50/90 value was (0.75/2μg/mL) and (0.25/2μg/mL) respectively. Conclusion: Cefiderocol exhibits superior activity against ESBL coliform and MDR   A. baumannii, P. aeruginosa compared to ceftolozane-Tazobactam.
Keywords
Ceftolozane-tazobactam; Cefiderocol; ESBL Enterobacterales; P. aeruginosa
Statistics
Article View: 226
PDF Download: 202